 Home > Medical News > Latest Medical News > Dongsian benzoic acid agritin tablets received a drug registration certificate approved by NMPA

Dongsian benzoic acid agritin tablets received a drug registration certificate approved by NMPA

 Last Update: 2021-01-01
 Source: Internet
 Author: User

Tags

parainfluenza type 2

epinephrine drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Dongsan announced that its controlling subsidiary Yang Yukang Pharmaceuticals has received the "Drug Registration Certificate" approved and issued by NMPA.
Aglitin (C18H21N5O2) is a drug of the type 4 inhibitor of ddipeptidease ("DPP-4 inhibitor") for the treatment of type 2 diabetes in adults.
These drugs can inhibit the inactivation of glucaucose-like peptide-1 ("GLP-1") and glucose-dependent insulin secretion peptides ("GIP"), improve endogenetic GLP-1 and GIP levels, promote insulin release by islet β cells, and inhibit islet α cellular secretion of glucagolytin, thereby increasing insulin levels, lowering blood sugar, and not easily inducing hypoglycemia and increased blood sugar.
At present, the production enterprises of benzoic acid Aglitin tablets are mainly Jiangsu Huashitong Biopharmaceutical Technology Co., Ltd., Jiangsu Deyuan Pharmaceutical Co., Ltd., Jiangsu Notai Aussie Biopharmaceutical Co., Ltd., Guorui Pharmaceutical Co., Ltd., etc.
is a Category B variety in the 2019 edition of the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs.
according to Ames China data, sales of DEP-4 inhibitors in public medical institutions in China amounted to about $259 million in 2019, up about 52.61 percent from 2018, making it one of the leading drugs used in diabetes treatment.
the product is one of 27 generic drug Aglitin tablets purchased by Yichang Dong Sunshine Changjiang Pharmaceutical Co., Ltd., a controlling subsidiary of the company, from its affiliate Guangdong Dongsian Pharmaceutical Co., Ltd. in 2019 at a transaction price of 6.6262 million yuan.
source: East Sunshine Enterprise Announcement

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.